Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Updated Treatment Guidelines ! I hope we make 2025 list !
View:
Comment by Infinity on Apr 14, 2024 9:36am
I was hoping to see some mention of PDT as an alternative to BCG unresponsive NMIBC.   Not even "C" which is a kind of level 3 methodology for Managing NMIBC.  There is only a broad mention in one paragraph. that is Quoted here.  Yes  hopefully we make it the next updates for AUA "The optimal management for patients with persistent or recurrent high-grade ...more  
Comment by O12009 on Apr 14, 2024 10:25am
Ladies and gentleman it is very easy to see why nobody has heard of Theralase Technologies and their drug Ruvdar. We are on the ground floor of this investment at the most important moment for this all to come together.  The Small private placement that appears to be in the works is a great place for big investors to climb aboard and for the everyday guy the stock is as cheap as it can be ...more  
Comment by menoalittle on Apr 14, 2024 10:55am
>> The Small private placement that appears to be in the works is a great place for big investors to climb aboard  now that seems to be a rather silly statement.  Because it doesn't look to me like there was actually any room in a small private placement such as this was (not "is") for "big" investors... unless your definition of a big investors is ...more  
Comment by Oilminerdeluxe on Apr 14, 2024 11:11am
Hopefully, the last one before BTD. However, if that drags on, how long can they keep doing these small raises? One or two more, or? The well will run dry one day. Not saying things will be delayed further, but they have had a tendency to do so in the past.. Unless the next update says otherwise, then perhaps Q2 is still where we get what we want. Would be a wonderful thing.
Comment by Kayz88 on Apr 14, 2024 1:20pm
I'm mentally prepared for Q4 of 2024 for BTD. 
Comment by menoalittle on Apr 14, 2024 1:40pm
BTD isn't the only thing that can or will move the price up this stock up significantly. But, what do I know...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250